The European Commission is predicting that by 2020 Europe will need an additional one million clinical professionals to care for its ageing population. With many of our cancer systems already working at full capacity, this [more]
Patients look for the best treatment centres, says this leading voice in European urology. So theyll go where the specialists involved in their care work together, not where they are constantly battling over who is [more]
Recent years have seen a revival of interest in the unique metabolism of cancer cells. This time the focus is on the potential it offers as a target, rather than any possible causal role [more]
Patient advocates believe their input into guiding the research process is key to ensuring the right questions are investigated in the right way. Where its been successfully tried, both sides agree there is no going [more]
Getting cancer as a teenager or young adult can severely disrupt an important period of emotional, physical and social transition. Tailoring services to fit the particular needs of this age group can make a huge [more]
A shared sense of the value of helping people with incurable cancers achieve lives worth living has driven doctors to collaborate across borders for decades. An oncologist shares his experiences from the Cold War to [more]
If Tomasetti and Vogelstein had not used the words bad luck in their paper on how variation in cancer risk among tissues can be explained by the number of stem cell divisions, the media might [more]
Over the past decade, genetic testing for rare inherited mutations, such as BRCA1 and BRCA2 mutations, has been successfully incorporated into clinical practice. Next-generation sequencing of cancer-susceptibility genes and entire tumour genomes has transformed cancer [more]
We need to greatly improve our ability to monitor the impact of treatments on outcomes. ‘The right treatment, for the right person, at the right time’, represents a significant shift from ‘one-size-fits-all’ medicine to a [more]
How do you decide which new cancer drugs to approve, when statistical certainty takes too long to wait for and essential evidence on quality of life is hard to measure? The head of the cancer [more]
The side effects of targeted drugs are poorly documented, and their impact on patients frequently seriously underestimated and undertreated. Efforts to address these issues could improve survival as well as quality of life. The image [more]
Generics markets are gearing up for the expiry of patents on some of the first targeted cancer drugs. Its good news for greater access, but patients want reassurance that switching to generics wont put them [more]